Prevalence of hepatitis C virus and risk factors among drug users in Taizhou City of Zhejiang Province， 2009‒2020
10.19428/j.cnki.sjpm.2022.21524
- VernacularTitle:2009—2020年浙江省台州市吸毒人群丙型肝炎感染状况及影响因素分析
- Author:
Hongbiao LIANG
1
;
Shanling WANG
1
;
Yuanyuan XU
1
;
Guixia LI
1
;
Congcong LI
1
;
Xing LIU
2
;
Xiaoxiao CHEN
1
;
Haijiang LIN
1
Author Information
1. Taizhou Prefectural Center for Disease Control and Prevention, Taizhou, Zhejiang 318002, China
2. Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
- Publication Type:Journal Article
- Keywords:
drug user;
hepatitis C virus;
infection status;
risk factor
- From:
Shanghai Journal of Preventive Medicine
2022;34(4):326-330
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo determine the prevalence of hepatitis C virus （HCV） infection and identify the underlying risk factors among drug users in Taizhou City of Zhejiang Province during 2009‒2020. MethodsA consecutive cross-sectional survey was conducted. A total of 400 drug users in correctional settings were randomly selected from April to August. The drug users were interviewed with a questionnaire to collect demographic characteristics， AIDS-related knowledge， detoxification service， drug use， and sexual behavior. Blood samples were then collected for anti-HCV antibody testing. Chi-square test and multivariate conditional logistic regression were used. ResultsA total of 5 042 drug users were included in this study. Seroprevalence of HCV was determined to be 22.7%. From 2009 to 2019， the seroprevalence showed a significant downward trend， from 34.9% to 8.8% （χ2=221.025， P<0.001）. However， in 2020， the seroprevalence was 12.7%. The multivariate logistic regression analysis showed that senior age （≥25 years old）， cohabitation， taking traditional or mixed drugs， injection drug use， and needle sharing were risk factors associated with HCV seroprevalence. ConclusionSince 2009， HCV seroprevalence among drug users in Taizhou City has shown a downward trend， however， it has increased slightly in 2020. It warrants strengthening prevention and treatment measures in response to risk factors related to HCV infection among drug users.
